Scarica l'app Stockscreener
453.36
0.33%
1.322
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$452.04
Aprire:
$454.28
Volume 24 ore:
634.10K
Relative Volume:
0.43
Capitalizzazione di mercato:
$115.06B
Reddito:
$11.74B
Utile/perdita netta:
$3.68B
Rapporto P/E:
31.95
EPS:
14.1888
Flusso di cassa netto:
$3.34B
1 W Prestazione:
+2.59%
1M Prestazione:
+3.74%
6M Prestazione:
-0.43%
1 anno Prestazione:
-2.20%
Intervallo 1D:
$449.48
$454.62
Intervallo di 1 settimana:
$433.81
$456.00
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
453.50 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.39 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.16 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
394.74 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.59 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
12 Days of Investing: My Top 12 Stocks to Buy Before 2026 - The Motley Fool
National Bank of Canada FI Acquires 99,751 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Castleark Management LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
B. Riley Wealth Advisors Inc. Buys Shares of 4,141 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
MASTERINVEST Kapitalanlage GmbH Purchases Shares of 5,784 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Westwood Holdings Group Inc. - MarketBeat
Lazard Asset Management LLC Has $213.83 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Provident Investment Management Inc. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Position Lifted by Liontrust Investment Partners LLP - MarketBeat
Marex Group plc Invests $2.98 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Coppell Advisory Solutions LLC Buys 2,846 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025? - Yahoo Finance
How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX is Bellevue Group AG's 8th Largest Position - MarketBeat
2 Healthcare Stocks to Buy Ahead of the New Year - The Globe and Mail
Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know - MSN
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Sei Investments Co. Has $132.41 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CIBC Asset Management Inc Sells 4,393 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - Finviz
Alliancebernstein L.P. Has $1.95 Billion Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025) - ts2.tech
United States Orphan Drugs Market to Reach USD 486.51 Billion - openPR.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $515.00 at Wells Fargo & Company - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Investment Management Corp of Ontario - MarketBeat
This Week’s CGT News: Vertex’s Gene Therapies Show Promise in Younger Children - The Medicine Maker
Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $515 From $460, Maintains Overweight Rating - marketscreener.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Jump Financial LLC - MarketBeat
Ossiam Has $2.05 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Diadema Partners LP Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank of Nova Scotia Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
State Street Corp Has $5.24 Billion Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by SVB Wealth LLC - MarketBeat
Daiwa Securities Group Inc. Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Axa S.A. Buys 10,477 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
Disney, Nu Holdings, Phillips 66 And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
Vertex Will Seek Regulatory Approval for Casgevy in Younger Sickle Cell, Beta-Thalassemia Patients - Precision Medicine Online
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Vertex's Gene Therapy Works In Children With Blood Disorders - Benzinga
Thematics Asset Management Acquires 2,642 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - BioSpace
Federated Hermes Inc. Acquires 23,726 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
David And Goliath: How A Parent-Led Buyers’ Club Challenged Cystic Fibrosis Giant Vertex - Citeline News & Insights
VRTX Stock Quote Price and Forecast - CNN
Marshall Wace LLP Has $52.09 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
California Public Employees Retirement System Has $322.79 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cerity Partners LLC Purchases 10,768 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
5.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):